• Tuesday, September 4, 2018 @ 8:00 am

ProteoMediX AG, a diagnostic company developing blood-based tests for the accurate diagnosis and prognosis of prostate cancer, has announced the successful closing of an equity financing round. The company raised CHF 5.2 million (€ 4.6 million) from existing investors. 

Find the full media release here.

You may also be interested in